Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT00003065

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Phase 1

Completed

Conditions: Endometrial Clear Cell Adenocarcinoma
Stage III Uterine Corpus Cancer
Endometrial Serous Adenocarcinoma
Stage IV Uterine Corpus Cancer

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Radiation: Radiation Therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 35

Registration Number: NCT00005840

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Phase 2

Completed

Conditions: Thymoma
Thymic Carcinoma

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 46

Registration Number: NCT00010257

Locations: 🇺🇸
HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, Minnesota, United States
🇺🇸
Mount Nittany Medical Center, State College, Pennsylvania, United States
🇺🇸
MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States

and more 64 locations

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: bevacizumab

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 722

Registration Number: NCT00028990

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States

and more 27 locations

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00014118

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 44 locations

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Phase 3

Completed

Conditions: Endometrial Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-22

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00006027

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Community Hospital of Los Gatos, Los Gatos, California, United States

and more 26 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2003-01-27

Last Posted Date: 2017-02-23

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT00002931

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 69

Registration Number: NCT00032032

Locations: 🇺🇸
McFarland Clinic, PC, Ames, Iowa, United States
🇺🇸
Community Cancer Center of Monroe, Monroe, Michigan, United States
🇺🇸
Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States

and more 48 locations

Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 300

Registration Number: NCT00039039

Locations: 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇮🇹
Ospedale Mariano Santo, Cosenza, Italy
🇮🇹
Ospedale San Martino, Genoa, Italy

and more 34 locations

Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 70

Registration Number: NCT00011999

Locations: 🇺🇸
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 231 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy